SPARC Shares Jump 20% After US Court Clears Sezaby PRV Case

Shares of Sun Pharma Advanced Research Company (SPARC) soared 20% on December 2 after a US District Court granted summary judgment in favour of the company regarding the Priority Review Voucher (PRV) tied to its Sezaby injection. The ruling overturned the earlier withholding of the PRV by the US Food and Drug Administration (FDA), clearing a key regulatory hurdle and triggering strong investor demand. The stock hit its upper circuit at ₹161.02 on heavy volume, reflecting renewed confidence in SPARC’s regulatory pathway.